Sunday, 12 November 2017

Sponsored Session
10:00 - 13:00
Room "Castor 1"

**SS1, Pre-Congress Symposia**

Clinical Practice Session
13:30 - 15:00
Room "Pollux 1"

**G1, Introduction to Parkinson Disease**

**Learning Objectives**
- To outline the clinical definition of Parkinson disease
- To describe the signs of Parkinson disease that precede motor manifestations
- To describe the time course of motor signs in Parkinson disease

Chair: Carlos Singer (Miami, FL, United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 14:00</td>
<td><strong>The Clinical Definition of Parkinson Disease</strong></td>
<td>Erik Ch. Wolters (Amsterdam, Netherlands)</td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td><strong>Pre-Motor Manifestations in Parkinson Disease</strong></td>
<td>Caroline Tanner (San Francisco, CA, United States)</td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td><strong>Early and Late Motor Manifestations of Parkinson Disease</strong></td>
<td>Tanya Simuni (Chicago, IL, United States)</td>
</tr>
</tbody>
</table>

Timeline Parallel Session
13:30 - 15:00
Room "Pollux 2"

**F2, From Mice to Primates: New Animal Models of Movement Disorders**

**Learning Objectives**
- To describe the major animal models in Parkinson disease
- To describe the emerging animal models in progressive supranuclear palsy
- To describe the advances in animal models of dystonia

Chair: Antonio Pisani (Rome, Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 14:00</td>
<td><strong>The Most Promising Models in Parkinson’s Disease</strong></td>
<td>Antonio Pisani (Rome, Italy)</td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td><strong>Emerging Models in Progressive Supranuclear Palsy</strong></td>
<td>Etienne Hirsch (Paris, France)</td>
</tr>
</tbody>
</table>
**Pho Hot Topic Session**
13:30 - 15:00

**C2, Focusing on Genetics and Imaging in Movement Disorders**

**Learning Objectives**
- To explain the status of gene based therapies for movement disorders
- To describe genetic testing in movement disorders
- To discuss the current status of imaging techniques in understanding movement disorder pathology

Chair: Shinsuke Fujioka (Fukuoka, Japan)
Chair: Andreas Puschmann (Lund, Sweden)

- **The Promise of Gene Based Technology in Movement Disorders**
  Speaker: Nobutaka Hattori (Tokyo, Japan)
  13:30 - 14:00

- **The Most Relevant Advances in Genetic Testing in Movement Disorders**
  Speaker: Hui-Fang Shang (Chengdu, Sichuan, China)
  14:00 - 14:30

- **Imaging Techniques That are Leading the Way in Understanding Movement Disorders**
  Speaker: Jon Stoessl (Vancouver, Canada)
  14:30 - 15:00

**Point-Counterpoint Interactive Session**
13:30 - 15:00

**D3, Dementia With Lewy Bodies and Parkinson Disease Dementia: Is It the Same Disease?**

**Learning Objectives**
- To outline the evidence for and against considering dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) as the same disease

Chair: Carlo Colosimo (Terni, Italy)

- **Dementia With Lewy Bodies and Parkinson Disease Dementia: It is the Same Disease!**
  Speaker: Joseph Friedman (Rhode Island, United States)
  13:30 - 14:00

- **Dementia With Lewy Bodies and Parkinson Disease Dementia: It is NOT the Same Disease!**
  Speaker: Francesc Valldeoriola (Barcelona, Spain)
  14:00 - 14:30

- **Debate**
  14:30 - 14:45

- **Question and Answer**
  14:45 - 15:00

**Oral Poster Session**
13:30 - 15:00

**OP-1, Oral Poster Presentation - Session I Basic Neuroscience & Other Movement Disorders**

Chair: Lorraine Kalia (Toronto, Canada)
Chair: Alberto Espay (Cincinnati, OH, United States)
Botulinum toxin: central or peripheral mechanism of action?
Speaker: Zdravko Lackovic (Zagreb, Croatia)

Reprogramming in inflammatory response to neuronal damage induced by the brain LPS preconditioning: possible implications in rat model of Parkinson's disease
Speaker: Mojtaba Golpich (Kuala Lumpur, Malaysia)

Clinico-genetic correlation in Indian Spinocerebellar ataxia Type 1 (SCA1) patients
Speaker: Amit Takkar (Delhi, India)

Prevalence of hemochromatosis (HFE) gene mutations in Friedreich's Ataxia patients and peripheral neuropathy
Speaker: Inder Singh (New Delhi, India)

Movement disorders in patients with Japanese encephalitis: Experience in a tertiary care hospital in North Eastern region of India
Speaker: Amit Ranjan Barua (Guwahati, India)

Voxel-based meta-analysis of gray and white matter volume reductions in spinocerebellar ataxia type 2
Speaker: Qing Han (Chengdu, China)

Non-motor symptoms in patients with autosomal dominant spinocerebellar ataxia
Speaker: Nitish Kamble (Bangalore, India)

Identification of MicroRNAs and their target genes modulating Spinocerebellar Ataxia type-2 (SCA2) pathogenesis
Speaker: Vishnu Swarup (New Delhi, India)

Prevalence of Parkinson’s disease and drug-induced Parkinsonism from National Health Insurance Service Claims Data (NHISCD)
Speaker: Hyeo-Il Ma (Anyang, Korea, Republic of)

Clinical profile of normal pressure hydrocephalous patients with suggested phenotypic variants
Speaker: Mrinal Kumar Acharya (Kolkata, India)

Phenotypic differences in genetically characterized Spinocerebellar Ataxia Type 2(SCA2): a largest case series from India
Speaker: Akhilesh Kumar Sonakar (New Delhi, India)

Clinical features and differential diagnostic criteria of PANDAS syndrome and Sydenham’s chorea
Speaker: Iroda Nasirova (Tashkent, Uzbekistan)

To study the genotype - phenotype correlation of Friedreich's Ataxia (FRDA) patients in Indian population
Speaker: Istaq Ahmad (Delhi, India)

Meeting the Professor
13:30 - 15:00
Meet the Professor Lounge (Exhibition)

J1, Meet the Professor 1
Professor: Joachim Krauss (Hannover, Germany)
B1, Can Biomarkers Lead Us to Understanding and Conquering Parkinson Disease?

Learning Objectives
- To describe the general features of biomarkers in Parkinson disease
- To understand the use of biomarkers to aid in early diagnosis of Parkinson disease
- To review the status of biomarkers in cognition and behavior in Parkinson disease

Chair: Erik Ch. Wolters (Amsterdam, Netherlands)
Chair: Daniel Truong (Fountain Valley, CA, United States)

Unlocking the Mystery of Biomarkers: A Brief Introduction, Its Challenges and Opportunities in Parkinson Disease
Speaker: Alice Chen-Plotkin (Philadelphia, PA, United States)
15:30 - 16:00

How Biomarkers Are Uncovering Rate of Parkinson's Disease Progression
Speaker: Jennifer Yarden (Haifa, Israel)
16:00 - 16:30

The Emerging Role of Biomarkers in Cognition and Behavior in Parkinson Disease
Speaker: Lorraine Kalia (Toronto, Canada)
16:30 - 17:00

Plenary Session
17:30 - 19:00

OC, Opening Ceremony & Melvin Yahr Lectures

Traditional Vietnamese drum performance
17:30 - 17:35

Welcome
Speaker: Daniel Truong (Fountain Valley, CA, United States)
17:35 - 17:45

Melvin Yahr lecture I: The 200 Year Journey of Parkinson Disease: Reflecting on the Past and Looking Towards the Future
Speaker: Stanley Fahn (New York, NY, United States)
17:45 - 18:15

Melvin Yahr lecture II: Deep Brain Stimulation Surgery in Movement Disorders: Lessons From The Last 3 Decades
Speaker: Elena Moro (Grenoble, France)
Speaker: Joachim Krauss (Hannover, Germany)
18:15 - 18:45

Performance of the Vietnamese dance group
18:45 - 19:00

Closing
Speaker: Daniel Truong (Fountain Valley, CA, United States)
19:00 - 19:05

Performance of the Vietnamese dance group
19:05 - 19:15
Clinical Practice Session
08:30 - 10:00
Room "Pollux 1"

**G2, Autonomic Dysfunction in Parkinson Disease**

**Learning Objectives**
- To characterize cardiovascular dysfunction in Parkinson disease
- To characterize gastrointestinal complications in Parkinson disease
- To characterize urogenital issues in Parkinson disease

Chair: Ronald Pfeiffer (Portland, OR, United States)
Chair: Hung Truong Nguyen (Hanoi, Viet Nam)

- **Cardiovascular Dysfunction in Parkinson Disease** 08:30 - 09:00
  Speaker: Horaico Kaufmann (New York, NY, United States)

- **Gastrointestinal Complications in Parkinson Disease** 09:00 - 09:30
  Speaker: Ailton Melo (Salvador, Brazil)

- **Urogenital Issues in Parkinson Disease** 09:30 - 10:00
  Speaker: Karen Frei (Loma Linda, CA, United States)

Clinical Practice Session
08:30 - 10:00
Room "Pollux 2"

**G3, Neuropathology and Behavioral Dysfunction in Parkinson Disease**

**Learning Objectives**
- To describe the neuropathology of Parkinson disease
- To characterize symptoms of fatigue, apathy, and depression in Parkinson disease
- To outline the similarities and differences of Parkinson disease dementia (PDD) and dementia with Lewy bodies

Chair: Stuart Isaacson (Boca Raton, FL, United States)

- **Neuropathology of Parkinson Disease** 08:30 - 09:00
  Speaker: Dennis Dickson (Jacksonville, FL, United States)

- **Fatigue, Apathy and Depression in Parkinson Disease** 09:00 - 09:30
  Speaker: Joseph Friedman (Rhode Island, United States)

- **The Overlapping Syndromes of Parkinson Disease Dementia and Dementia With Lewy Bodies** 09:30 - 10:00
  Speaker: Irena Rektorova (Brno, Czech Republic)

Pho Hot Topic Session
08:30 - 10:00
Room "Castor 1"

**C3, Focusing on New Targets for Therapy**

**Learning Objectives**
- To discuss the glucocerebrosidase (GBA) gene and its potential as a therapeutic target
- To discuss glucagon-like peptide -1 and its potential as a therapeutic target
- To discuss alpha synuclein antibodies as therapies

Chair: Tanya Simuni (Chicago, IL, United States)

- **Spotlight on Glucocerebrosidase** 08:30 - 09:00
  Speaker: Weidong Le (Dalian, China)
Spotlight on Glucagon-Like Peptide-1 09:00 - 09:30
Speaker: Shinsuke Fujioka (Fukuoka, Japan)

Spotlight on the Alpha Synuclein Antibodies 09:30 - 10:00
Speaker: Lorraine Kalia (Toronto, Canada)

Point-Counterpoint Interactive Session
08:30 - 10:00
Room "Castor 2"

**D2, Is Parkinson Disease a Prion Disease?**

_**Learning Objectives**_
- To understand the evidence for and against the hypothesis that Parkinson disease is a prion disease

Chair: Francesc Valldeoriola (Barcelona, Spain)

**Yes - Parkinson Disease is a Prion Disease!** 08:30 - 09:00
Speaker: Wassilios Meissner (Bordeaux, France)

**No - Parkinson Disease is NOT a Prion Disease!** 09:00 - 09:30
Speaker: James Surmeier (Chicago, IL, United States)

**Debate** 09:30 - 09:45

**Question and Answer** 09:45 - 10:00

Timeline Parallel Session
08:30 - 10:00
Room "Castor 3"

**F8, Treating the Most Challenging Behavioral and Cognitive Issues in Parkinson Disease**

_**Learning Objectives**_
- To understand the evolution of the treatment of psychosis in Parkinson disease
- To describe the history and treatment of impulse control behavior disorders in Parkinson disease
- To explain the challenges associated with dementia and its treatment in Parkinson disease

Chair: Hui-Fang Shang (Chengdu, Sichuan, China)

**The Evolution of PD Psychosis Treatment** 08:30 - 09:00
Speaker: Daniel Weintraub (Philadelphia, PA, United States)

**The Rise and Fall of Impulse Control Behavior Disorders** 09:00 - 09:30
Speaker: Carlo Colosimo (Terni, Italy)

**Facing the Challenges When Dementia Sets In** 09:30 - 10:00
Speaker: Mark Lew (Los Angeles, CA, United States)

Oral Poster Session
08:30 - 10:00
Poster Exhibition

**OP-2, Oral Poster Presentation - Session II Parkinson 1: Etiology/ Epidemiology/ Pathophysiology**

Chair: Antonio Pisani (Rome, Italy)
Chair: Emanuele Cereda (Pavia, Italy)

**The findings of dysphagia in patients with Parkinson’s disease, using videofluoroscopic study**
Speaker: Seong Hoon Lim (kyungki-do, Korea, Republic of)
Validity of the 5-item clock-drawing scoring system in screening of dementia in Parkinson’s disease patients
Speaker: Chanya Tangkanakul (Pathumthani, Thailand)

Depression and executive functions modulate motor-related brain activity in parkinsonians
Speaker: Jin Yan (Shenzhen, China)

LRRK2 variant is associated with lower risk of essential tremor
Speaker: Shin Hui Ng (Singapore, Singapore)

Prevalence of cerebral and cardiovascular disease in Parkinson’s disease patients: A meta-analysis
Speaker: Chien Tai Hong (New Taipei City, Taiwan)

White matter alterations in Parkinson’s disease with normal cognition precede grey matter atrophy
Speaker: Ivan Rektor (Brno, Czech Republic)

Epidemiology of Parkinson’s disease in Africa: challenges and opportunities
Speaker: Daniel Gams Massi (Dakar, Senegal)

Depression in Parkinson’s disease: A case-control study
Speaker: Ming-Hong Chang (Taichung, Taiwan)

Motor-symptom laterality affects acquisition in Parkinson’s disease: a cognitive and functional magnetic resonance imaging study
Speaker: Pei Huang (Shanghai, China)

Putaminal dopamine depletion patterns in de novo Parkinson’s disease predicts later development of motor complication types
Speaker: Young H. Sohn (Seoul, Korea, Republic of)

Variants in MCCC1/LAMP3 and DGKQ identified through GWAS are not associated with PD in a Malaysian Malay cohort
Speaker: Jia Lun Lim (Kuala Lumpur, Malaysia)

The modifying effect of age on survival in Parkinson’s disease: big data analysis
Speaker: Chava Peretz (Tel Aviv, Israel)

Association between serum uric acid levels and disease severity in Parkinson patients
Speaker: Phuong To Thi Bich (Nha Trang City, Viet Nam)

Apathy in drug-naïve patients with Parkinson’s disease
Speaker: Hui Liu (Chengdu, China)

Cardinal symptoms of Parkinson’s disease cohabit with levodopa-induced dyskinesia
Speaker: Etienne Goubault (Montréal, Canada)

The association of perceived stress and the frequency and severity of non-motor symptoms in Parkinson’s disease
Speaker: Melanie Cusso (Southport, Australia)

B2, Understanding the Complex Web of Cognitive Dysfunction and Movement Disorders

Learning Objectives
- To identify the scope of cognitive dysfunction in movement disorders
- To describe the tauopathies and the link between aggregated tau protein and cognitive dysfunction
- To describe cognitive dysfunction and movement disorders in adult-onset leukoencephalopathies

Chair: Eng-King Tan (Singapore, Singapore)
Chair: Peter Riederer (Wuerzburg, Germany)
The Spectrum of Mild Cognitive Impairment to Dementia in Parkinson Disease
Speaker: Daniel Weintraub (Philadelphia, PA, United States)
10:30 - 11:00

Untangling the Tauopathies
Speaker: Helen Ling (London, United Kingdom)
11:00 - 11:30

Cognitive Dysfunction and Movement Disorders in Adult-Onset Leukoencephalopathies
Speaker: Takeshi Ikeuchi (Niigata, Japan)
11:30 - 12:00

Plenary Session
13:30 - 15:00

B3, The Treatment of Parkinson Disease: 200 Years Later
Learning Objectives
- To describe the current pharmacotherapy of Parkinson disease
- To understand the current surgical treatments for Parkinson disease
- To explain the principal non-pharmacological therapies for Parkinson disease

Chair: Beom Jeon (Seoul, Korea, Republic of)
Chair: Sheng-Di Chen (Shanghai, China)

Pharmacological Advances in Parkinson Disease Treatment
Speaker: Fabrizio Stocchi (Rome, Italy)
13:30 - 14:00

The Current State of Functional Neurosurgical Therapy in Parkinson Disease
Speaker: Elena Moro (Grenoble, France)
14:00 - 14:30

The Most Promising Non-Pharmacological Therapies for Parkinson Disease
Speaker: Bastiaan Bloem (Nijmegen, Netherlands)
14:30 - 15:00

Skills Workshop
15:30 - 17:00

H1, Skills Workshop 1: Deep Brain Stimulation Surgery
Learning Objectives
- To define the optimal patient characteristics for deep brain stimulation
- To learn tips for deep brain stimulation programming
- To identify and manage complications of deep brain stimulation

Chair: Joachim Krauss (Hannover, Germany)
Chair: Thomas Bruecke (Vienna, Austria)
**Clinical Practice Session**
15:30 - 17:00

**G4, Therapy for Parkinson Disease Part I**

**Learning Objectives**
- To describe current medications for the treatment of Parkinson disease
- To explain the management of medication-induced motor side effects in the treatment of Parkinson disease
- To explain the management of medication-induced cognitive and behavioral side effects in the treatment of Parkinson disease

Chair: Andrzej Friedman (Warsaw, Poland)

**Current Conventional Pharmacotherapeutical Interventions**
15:30 - 16:00
Speaker: Rajesh Pahwa (Kansas City, KS, United States)

**Addressing Motor Pharmacotherapeutical Complications in Parkinson Disease**
16:00 - 16:30
Speaker: Thomas Mueller (Berlin, Germany)

**Addressing the Cognitive and Behavioral Pharmacotherapeutical Complications of Parkinson Disease**
16:30 - 17:00
Speaker: Stuart Isaacson (Boca Raton, FL, United States)

**Pho Hot Topic Session**
15:30 - 17:00

**C1, Focusing on Gut Microbiota**

**Learning Objectives**
- To explain gastrointestinal dysfunction and pathology in Parkinson disease
- To identify the major findings of gastrointestinal biopsy studies in Parkinson disease
- To describe future challenges in understanding the gut microbiota in Parkinson disease

Chair: Ivan Bodis-Wollner (Brooklyn, NY, United States)
Chair: Pramod Pal (Bengaluru, Karnataka, India)

**Past: Historical Overview and the Pathology of Gastrointestinal Dysfunctions in Parkinson Disease**
15:30 - 16:00
Speaker: Ailton Melo (Salvador, Brazil)

**Present: What We Have Learned from Gastrointestinal Biopsy Studies in Parkinson Disease?**
16:00 - 16:30
Speaker: Kathleen Shannon (Madison, WI, United States)

**Future Perspectives: The Enteric Glia, Small Intestinal Bacterial Overgrowth, and Microbiota in Parkinson Disease**
16:30 - 17:00
Speaker: Roberto Cilia (Milan, Italy)
Point-Counterpoint Interactive Session
15:30 - 17:00
Room "Castor 2"

D1, Are SPECT Scans Useful for the Diagnosis of Parkinson Disease and Other Parkinsonian Disorders?

Learning Objectives
- To appreciate the pros and cons of using SPECT scans for diagnosis of Parkinson and related diseases

Chair: Mark Lew (Los Angeles, CA, United States)

Yes: SPECT Scans are Useful for the Diagnosis of Parkinson Disease and Other Parkinsonian Disorders!
Speaker: Angelo Antonini (Venice, Padova, Italy)
15:30 - 16:00

No: SPECT Scans are NOT Useful for the Diagnosis of Parkinson Disease and Other Parkinsonian Disorders!
Speaker: Jon Stoessl (Vancouver, Canada)
16:00 - 16:30

Debate
16:30 - 16:45

Question and Answer
16:45 - 17:00

Timeline Parallel Session
15:30 - 17:00
Room "Castor 3"

F9, Are We Ready for Digital Technology in the Assessment and Management of Parkinson Disease?

Learning Objectives
- To summarize the benefits and drawbacks of traditional outcome measures in Parkinson disease
- To understand the uses of digital technology as clinical trial outcome measures
- To explain the benefits of wearable sensors in treating Parkinson disease

Chair: Roongroj Bhidayasiri (Bangkok, Thailand)

Historical Perspective: The Pros and Cons of Conventional Outcome Measures in Parkinson Disease
Speaker: Shen-Yang Lim (Kuala Lumpur, Malaysia)
15:30 - 16:00

The Present: The Invasion of Digital Technology in Parkinson Clinical Trials
Speaker: Alberto Espay (Cincinnati, OH, United States)
16:00 - 16:30

The Future: How Wearable Sensors Can Transform Parkinson Management
Speaker: Erwin Van Wegen (Amsterdam, Netherlands)
16:30 - 17:00

Oral Poster Session
15:30 - 17:00
Poster Exhibition

OP-3, Oral Poster Presentation - Session III Parkinson 1: Etiology/ Epidemiology/ Pathophysiology

Chair: Irena Rektorova (Brno, Czech Republic)
Chair: Ioannis Isaias (Wuerzburg, Germany)

Objective versus subjective assessments of freezing of gait: An observational study of patients with Parkinson’s disease and related disorders in Singapore
Speaker: Shuang Yu Nicole Chia (Singapore, Singapore)
Oral health of Parkinson’s disease patients, a case-control study  
Speaker: Cees de Baat (Oegstgeest, Netherlands)

Rare GCH1 heterozygous variants contributing to Parkinson’s disease  
Speaker: Jifeng Guo (Changsha, China)

Rapid eye movement behavior disorder in drug-naïve patients with Parkinson’s disease  
Speaker: Hui Liu (Chengdu, China)

Patients and their caregivers’ burdens for Parkinson's disease in Korea  
Speaker: Jong Sam Baik (Seoul, Korea, Republic of)

Greater motor progression in patients with Parkinson disease who carry Park 16 variant  
Speaker: Xiao Deng (Nanning, China)

The association between early treatment with amantadine and delayed onset of levodopa-induced dyskinesia in patients with Parkinson’s disease  
Speaker: Tsai Ling Wu (Taipei, Taiwan)

Clinical features and life quality in normosmic Parkinson's Disease  
Speaker: ShiShuang Cui (Shanghai, China)

Glucocerebrosidase gene mutation in Parkinson’s disease  
Speaker: Mabel Macas (Manila, Philippines)

Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson’s disease  
Speaker: Jinho Kim (Gwanju, Korea, Republic of)

Comorbid conditions associated with Parkinson’s disease: a population-based study from the Nebraska Parkinson’s Disease Registry  
Speaker: John Bertoni (Omaha, United States)

Reduced arm swing during gait in patients with Parkinson disease: objective motion analysis study  
Speaker: Young Min Park (Seoul, Korea, Republic of)

Body composition, sarcopenia and frailty in a multi-ethnic Asian cohort with Parkinson’s disease  
Speaker: Ai Huey Tan (Kuala Lumpur, Malaysia)

Diagnostic value of striatal-prefrontal projection estimated by cerebral blood flow and dopamine transporter SPECT in Parkinsonian syndromes  
Speaker: Yoshikazu Nakano (Chiba, Japan)

Pain in Parkinson disease: a local single-center correlational study of ambulatory parkinson disease patients  
Speaker: Michelle Ann C. Sy (Manila, Philippines)

**Meeting the Professor**  
15:30 - 17:00  
Meet the Professor Lounge (Exhibition)

**J2, Meet the Professor 2**  
Professor: Stanley Fahn (New York, NY, United States)

**Meetings**  
17:15 - 18:45  
Plenary  
**IAPRD Annual General Meeting**  
Chair: Daniel Truong (Fountain Valley, CA, United States)
Tuesday, 14 November 2017

Clinical Practice Session
08:30 - 10:00
Room "Pollux 1"

G5, Therapy for Parkinson Disease Part II

Learning Objectives
- To describe non-pharmacologic treatments for Parkinson disease
- To understand the role of medications that continuously stimulate the dopaminergic system in Parkinson disease
- To explain the use of surgical interventions such as deep brain stimulation in Parkinson disease

Chair: Yih-Ru Wu (Taoyuan, Taiwan)
Chair: van Tuan Le (Ho Chi Minh City, Viet Nam)

08:30 - 09:00  
Non-Pharmacotherapeutical Interventions in Parkinson Disease  
Speaker: Jawad Bajwa (Riyadh, Saudi Arabia)

09:00 - 09:30  
The Role of Continuous Dopaminergic Stimulation in Parkinson Disease  
Speaker: Angelo Antonini (Venice, Padova, Italy)

09:30 - 10:00  
Surgical Interventions in Parkinson Disease  
Speaker: Joachim Krauss (Hannover, Germany)

Global Video Session
08:30 - 10:00
Room "Pollux 2"

E1, Phenomenology of Movement Disorders

Learning Objectives
- To recognize the clinical signs of hypokinesias
- To recognize the clinical signs of hyperkinesias
- To recognize the clinical signs of less common movement disorders

Chair: Raymond Rosales (Quezon City, Philippines)

08:30 - 09:00  
The Most Relevant Hypokinetic Disorders  
Speaker: Ramon Rodriguez (Gainesville, FL, United States)

09:00 - 09:30  
Hyperkinetic Disorders Everyone Needs to Recognize  
Speaker: Shen-Yang Lim (Kuala Lumpur, Malaysia)

09:30 - 10:00  
The Most Unusual and Fascinating Movement Disorders  
Speaker: Roongroj Bhidayasiri (Bangkok, Thailand)

Pho Hot Topic Session
08:30 - 10:00
Room "Castor 1"

C4, Focusing on the Multidisciplinary Approach to Parkinson Disease and Other Movement Disorders

Learning Objectives
- To learn about the importance of rehabilitation and exercise in Parkinson disease
- To describe treatment of sexual dysfunction in movement disorders
- To understand the importance of nutrition in Parkinson disease

Chair: Diego Torres-Russotto (Omaha, NE, United States)
Chair: Minh Le (Ho Chi Minh City, Viet Nam)
Run, Pedal, Stretch: The Inevitable Role of Rehabilitation and Exercise in Parkinson Disease 08:30 - 09:00
Speaker: Jay Alberts (Cleveland, OH, United States)

Bedtime Stories: Addressing Sexual Dysfunction in Movement Disorders 09:00 - 09:30
Speaker: Carlos Singer (Miami, FL, United States)

The Most Relevant Nutritional Issues in Parkinson Disease 09:30 - 10:00
Speaker: Emanuele Cereda (Pavia, Italy)

Point-Counterpoint Interactive Session
08:30 - 10:00
Room "Castor 2"

D4, Deep Brain Stimulation in Early Parkinson Disease: Is it Ready for Prime Time?
Learning Objectives
- To understand the pros and cons of deep brain stimulation for early Parkinson disease

Chair: Jean-Philippe Azulay (Marseille, France)
Chair: Tai Tran (Ho Chi Minh, Viet Nam)

Deep Brain Stimulation in Early Parkinson Disease: It is Ready for Prime Time! 08:30 - 09:00
Speaker: Michele Tagliati (Los Angeles, CA, United States)

Deep Brain Stimulation in Early Parkinson Disease: It is NOT Ready for Prime Time! 09:00 - 09:30
Speaker: Beom Jeon (Seoul, Korea, Republic of)

Debate 09:45 - 09:45

Question and Answer 09:45 - 10:00

Timeline Parallel Session
08:30 - 10:00
Room "Castor 3"

F1, Dystonia: Past, Present and Future
Learning Objectives
- To understand the history of dystonias
- To learn the pathophysiology of dystonia and current treatment options
- To outline recent dystonia findings and potential future treatments

Chair: Hyder Jinnah (Atlanta, GA, United States)

The Colorful History of Dystonia 08:30 - 09:00
Speaker: Dirk Dressler (Hannover, Germany)

The Pathophysiology of Dystonia and Its Current Treatment 09:00 - 09:30
Speaker: Hyder Jinnah (Atlanta, GA, United States)

The Most Promising Advances and Future Treatments 09:30 - 10:00
Speaker: Marie Vidailhet (Paris, France)
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study
Speaker: Gianni Pezzoli (Pavia, Italy)

Physical activity and its impact on non-motor aspects of Parkinson's disease - The early Parkinson's disease Longitudinal Singapore (PALS) study
Speaker: Yong Ern Samuel Ng (Singapore, Singapore)

Beneficial effect of laughter yoga and clapping exercise in Parkinson’s disease patients in south Delhi metro population
Speaker: Vinod Sharma (New Delhi, India)

Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in subjects with Parkinson's disease: preliminary results from the Phase-3 study dose-titration phase
Speaker: Alberto Espay (Cincinnati, OH, United States)

Depression in Parkinson's disease: relation with the level of "given up" activities
Speaker: Sarah Bogard (Montréal, Canada)

Long-term efficacy of inhaled levodopa in Parkinson's disease subjects with motor fluctuations: interim results of a phase 3 study
Speaker: Charles Oh (Ardsley, United States)

Pooled analysis of phase 3 studies of ADS-5102 for levodopa-induced dyskinesia: A detailed review of MDS-UPDRS, part IV (motor complications)
Speaker: Caroline Tanner (San Francisco, CA, United States)

The influence of smell and taste disturbances on the nutritional status in Parkinson disease
Speaker: Magdalena Koszewicz (Wroclaw, Poland)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06649751, an oral Dopamine D1/D5 agonist, in Parkinson's disease: A single ascending dose study
Speaker: David Gray (Cambridge, United States)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral Dopamine D1/D5 agonist PF-06649751 in Parkinson's disease: A multiple ascending dose study
Speaker: David Gray (Cambridge, United States)

Therapeutic effect of non-invasive vagus nerve stimulation in gait disturbance and freezing in Parkinson's disease patients
Speaker: Banashree Mondal (Kolkata, India)

The availability of anti-Parkinsonian drugs in Thailand and associated factors
Speaker: Karn Sakdisornchai (Bangkok, Thailand)

Value of intraoperative neurophysiological monitoring for clinical outcome of deep brain stimulation of subthalamic nucleus in Parkinson's disease
Speaker: Anna Gamaleya (Moscow, Russian Federation)

A naturalistic observation on 20 consecutive patients under LCIG at the “Tor Vergata” University; enforced counseling and alternative route of LD delivery for avoiding discontinuation?
Speaker: Alessandro Stefani (Rome, Italy)
Plenary Session
10:30 - 12:00

**B4, Revisiting the Classical Motor Disorders Impacting the Globe**

**Learning Objectives**
- To describe parkinsonism, its variation around the globe, and treatment evolution
- To describe dystonia, its variation around the globe, and treatment evolution
- To describe tremor, its variation around the globe, and treatment evolution

Chair: Rupam Borgohain (Hyderabad, India)
Chair: Roongroj Bhidayasiri (Bangkok, Thailand)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-11:00</td>
<td><strong>Parkinsonism: Then and Now</strong></td>
<td>Fabrizio Stocchi (Rome, Italy)</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td><strong>Dystonia: Then and Now</strong></td>
<td>Cynthia Comella (Chicago, IL, United States)</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td><strong>Tremor: Then and Now</strong></td>
<td>Elan Louis (New Haven, CT, United States)</td>
</tr>
</tbody>
</table>

Sponsored Session
12:00 - 13:30

**SS4, Corporate Session 4**

Plenary Session
13:30 - 15:00

**B5, When Lightning Strikes Twice: Finding the Balance Between Motor Symptoms and Behavior in 3 Complex Movement Disorders**

**Learning Objectives**
- To understand the pathology, clinical characteristics, and treatment of Huntington disease
- To understand the pathology, clinical characteristics, and treatment of Tourette Syndrome
- To understand the clinical characteristics and treatment of psychogenic movement disorders

Chair: Cynthia Comella (Chicago, IL, United States)
Chair: Daniel Truong (Fountain Valley, CA, United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-14:00</td>
<td><strong>Huntington Disease: What We Have Learned Since the Gene was Discovered</strong></td>
<td>Joseph Jankovic (Houston, United States)</td>
</tr>
<tr>
<td></td>
<td><strong>The Colorful Spectrum of Tourette Syndrome and Its Medical, Surgical and Behavioral Therapies</strong></td>
<td>Jan Roth (Praha, Czech Republic)</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td><strong>The Most Promising Advances in our Understanding and Treatment of Psychogenic Movement Disorders</strong></td>
<td>Mark Hallett (Bethesda, MD, United States)</td>
</tr>
</tbody>
</table>

Vietnamese Session
15:30 - 17:00

**Vietnamese Movement Disorder Session**

Chair: Minh Le (Ho Chi Minh City, Viet Nam)
Chair: Huu Cong Nguyen (Ho Chi Minh City, Viet Nam)
Report on the Activity of a Movement Disorder Unit at the Teaching Hospital University Medical Center
Speaker: Ngoc Tai Tran (Ho Chi Minh City, Viet Nam)

Botulinum Neurotoxin A for the Treatment of Cervical Dystonia: A 5-Year Case Series Study
Speaker: Ngoc Tai Tran (Ho Chi Minh City, Viet Nam)

Cognitive Impairment and Dementia in Vietnamese Parkinsonian Patients: A Prevalence Study
Speaker: Cong Thang Tran (Ho Chi Minh City, Viet Nam)

Depression in Parkinson Disease: An Initial Study with the Beck Depression Inventory
Speaker: Thanh Binh Nguyen (Hanoi, Viet Nam)

Deep Brain Stimulation for Parkinson Disease and other Movement Disorders in Vietnamese Patients: Initial Results
Speaker: Anh Tuan Pham (Ho Chi Minh City, Viet Nam)

Acanthocytosis in Vietnam
Speaker: Trang Vo Nguyen Ngoc (Ho Chi Minh City, Viet Nam)

Mitochondrial-Membrane Protein-Associated Neurodegeneration (MPAN): A Case Report
Speaker: Thi Huyen Thuong Dang (Ho Chi Minh City, Viet Nam)

Timeline Parallel Session
15:30 - 17:00
Room "Castor 1"

F6, The Painful Truth About Pain in Movement Disorders
Learning Objectives
- To describe the clinical methods for evaluating pain in movement disorders
- To outline the assessment and treatment of pain in Parkinson disease
- To outline the assessment and treatment of pain in hyperkinetic disorders

Chair: Maja Relja (Zagreb, Croatia)

The Clinical Assessment of Pain in Movement Disorders
Speaker: Heinz Reichmann (Dresden, Germany)

The Approach to Pain in Parkinson Disease
Speaker: Raymond Rosales (Quezon City, Philippines)

When Movement Disorders Hurt: Addressing Pain in Hyperkinetic Disorders
Speaker: Maja Relja (Zagreb, Croatia)

Global Video Session
15:30 - 17:00
Room "Castor 2"

E4, Parade of Movement Disorders From Around the Globe
Learning Objectives
- To understand common movement disorders in Asia
- To understand common movement disorders in South America
- To understand common movement disorders in Africa

Chair: Hubert Fernandez (Cleveland, OH, United States)
Movement Disorders in Asia
Speaker: Thien T. Lim (George Town, Malaysia)

Movement Disorders in South America
Speaker: Oscar Bernal-Pacheco (Bogotá, Colombia)

Movement Disorders in Africa
Speaker: Oluwadamiola Ojo (Lagos, Nigeria)

Timeline Parallel Session
15:30 - 17:00

F4, Past, Present and Future of Huntington Disease Care

Learning Objectives
- To describe the clinical methods for evaluating pain in movement disorders
- To outline the assessment and treatment of pain in Parkinson disease
- To outline the assessment and treatment of pain in hyperkinetic disorders

Chair: Kathleen Shannon (Madison, WI, United States)
Chair: Gulnora Rakhimbaeva (Taskent, Uzbekistan)

Huntington Disease Care: From the Past to the Present
Speaker: Tiago Mestre (Ottawa, Canada)

The Current and Emerging Trends of Huntington Disease Care at Multidisciplinary Centers
Speaker: Kathleen Shannon (Madison, WI, United States)

Is There a Role for Deep Brain Stimulation Surgery in Huntington Disease?
Speaker: Jean-Philippe Azulay (Marseille, France)

Oral Poster Session
15:30 - 17:00

OP-5, Oral Poster Presentation - Session V The TOP 15 Presentations - Nominee for Best Poster

Chair: Christian Baumann (Zurich, Switzerland)
Chair: Elena Moro (Grenoble, France)

Evaluation of various movement disorders in patients of genetically proven Spino Cerebellar Ataxia: A study from a tertiary care center in Northern India
Speaker: Divya Madathiparambil Radhakrishnan (Delhi, India)

Impaired freeze response in psychogenic (functional) movement disorder patients during exposure to stress
Speaker: Selma Aybek (Bern, Switzerland)

MicroRNA-4639 is a regulator of DJ-1 expression and a potential diagnostic marker for early Parkinson’s disease
Speaker: Yimeng Chen (Shanghai, China)

Chronic Mucuna pruriens in Parkinson’s disease: a non-inferiority, randomised, crossover, phase-2b trial
Speaker: Roberto Cilia (Milan, Italy)

Visual spatial dysfunction and retinal nerve fiber layer thickness in patients with Parkinson Disease
Speaker: Pei Chiek Teh (Wilayah Persekutuan Kuala Lumpur, Malaysia)
Turn cranio-caudal signature assessment from inertial systems for mobility deficit identification in Parkinson’s disease patients
Speaker: Karina Lebel (Sherbrooke, Canada)

Long term results of the VANTAGE study: A prospective multicenter trial evaluating deep brain stimulation with a multiple source, constant current system in Parkinson’s disease
Speaker: Thomas Bruecke (Vienna, Austria)

Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson’s disease
Speaker: Daniel K. Ness (South San Francisco, United States)

An electrical muscle stimulation therapy for intractable tremor in Parkinson’s disease: a randomized sham-controlled trial of a tremor’s glove device
Speaker: Onanong Jitkritsadakul (Bangkok, Thailand)

Zonisamide improves Parkinsonism in Dementia with Lewy Bodies (DLB): A randomized double-blind placebo-controlled Phase 3 study
Speaker: Kazuko Hasegawa (Sagamihara, Japan)

Cooperative synthesis of dopamine by striatal non-dopaminergic neurons as a mechanism of neuroplasticity at parkinsonism
Speaker: Aleksandr Kim (Moscow, Russian Federation)

Effects of once-daily valbenazine on Tardive Dyskinesia by body region
Speaker: Scott Siegert (San Diego, United States)

Safety and efficacy of DaxibotulinumtoxinA for injection (RT002) in cervical dystonia (CD): Results of a phase 2, dose escalating study
Speaker: Daniel Truong (Fountain Valley, CA, United States)

Video amplification as a sensitive screening tool for orthostatic tremor
Speaker: Diego Torres-Russotto (Omaha, NE, United States)

Meeting the Professor
15:30 - 17:00
Meet the Professor Lounge (Exhibition)

J3, Meet the Professor 3
Professor: Mark Hallett (Bethesda, MD, United States)

Skills Workshop
17:30 - 19:00
Plenary

H2, Skills Workshop 2: Botulinum Toxin Injections

Learning Objectives
- To learn injection techniques for the treatment of blepharospasm, hemifacial spasm, and jaw dystonia with botulinum toxin
- To learn injection techniques for the treatment of cervical dystonia with botulinum toxin
- To learn injection techniques for the treatment of limb dystonia and spasticity with botulinum toxin

Chair: Daniel Truong (Fountain Valley, CA, United States)
Chair: Tai Tran (Ho Chi Minh, Viet Nam)

Blepharospasm, Hemifacial Spasm and Jaw Dystonia 17:30 - 17:55
Speaker: Mark S. LeDoux (Memphis, United States)

Cervical Dystonia 17:55 - 18:20
Speaker: Raymond Rosales (Quezon City, Philippines)

Limb Dystonia and Spasticity 18:20 - 18:45
Speaker: Ramon Rodriguez (Gainesville, FL, United States)
Clinical Practice Session  
17:30 - 19:00  
Room "Pollux 1"

**G8, Dystonia and Sleep Related Movement Disorders**

**Learning Objectives**
- To describe the pathophysiology and classification of dystonias
- To outline the signs, symptoms, and treatment of dystonias
- To summarize sleep-related movement disorders and their treatment

Chair: Dirk Dressler (Hannover, Germany)  
Chair: Trang Vo Nguyen Ngoc (Ho Chi Minh City, Viet Nam)

**Dystonia: Pathophysiology/Classification**  
17:30 - 18:00  
Speaker: Joohi Jimenez-Shahed (Houston, United States)

**Dystonia: Clinical Aspects/Treatment**  
18:00 - 18:30  
Speaker: Dirk Dressler (Hannover, Germany)

**Sleep-Related Movement Disorders**  
18:30 - 19:00  
Speaker: Christian Baumann (Zurich, Switzerland)

Clinical Practice Session  
17:30 - 19:00  
Room "Pollux 2"

**G9, Parkinson-Plus Syndromes**

**Learning Objectives**
- To summarize clinical aspects and treatment of multiple system atrophy
- To summarize clinical aspects and treatment of progressive supranuclear palsy
- To summarize clinical aspects and treatment of corticobasal degeneration and corticobasal syndrome

Chair: Heinz Reichmann (Dresden, Germany)

**Multiple System Atrophy**  
17:30 - 18:00  
Speaker: Paola Sandroni (New York, United States)

**Progressive Supranuclear Palsy**  
18:00 - 18:30  
Speaker: Alfonso Fasano (Toronto, Canada)

**Corticobasal Degeneration and Corticobasal Syndrome**  
18:30 - 19:00  
Speaker: Diego Torres-Russotto (Omaha, NE, United States)

Timeline Parallel Session  
17:30 - 19:00  
Room "Castor 1"

**F3, Essential Tremor: Reflecting on the Past, and Leaping into the Future**

**Learning Objectives**
- To characterize the signs and diagnosis of essential tremor and its evolution over time
- To analyze the contribution of genetic and environmental factors to essential tremor
- To describe current and potential future treatments for essential tremor

Chair: Ioannis Isaias (Wuerzburg, Germany)  
Chair: Saltanat Kamenova (Almaty, Kazakhstan)
**Global Video Session**  
17:30 - 19:00  
Room "Castor 2"

**E2, The Pearls and Pitfalls of Psychogenic Movement Disorders**

**Learning Objectives**
- To recognize and diagnose psychogenic movement disorders
- To recognize organic movement disorders that appear psychogenic
- To recognize psychogenic movement disorders that appear organic

Chair: Pramod Pal (Bengaluru, Karnataka, India)

**The Diagnosis and Clinical Manifestations of Psychogenic Movement Disorders**  
17:30 - 18:00  
Speaker: Stanley Fahn (New York, NY, United States)

**Organic Movement Disorders that Appear Psychogenic**  
18:00 - 18:30  
Speaker: Xin Xin Yu (Cleveland, OH, United States)

**Psychogenic Movement Disorders that Appear Organic**  
18:30 - 19:00  
Speaker: Alberto Espay (Cincinnati, OH, United States)

**Timeline Parallel Session**  
17:30 - 19:00  
Room "Castor 3"

**F5, Autoimmune Movement Disorders: Current Understanding and Future Directions**

**Learning Objectives**
- To understand immune-mediated autoimmune movement disorders and their treatment
- To understand paraneoplastic autoimmune movement disorders and their treatment
- To understand non-paraneoplastic autoimmune movement disorders and their treatment

Chair: Rukmini Mridula (Panjagutta, Hyderabad, India)

**Infection-Mediated Autoimmune Movement Disorders**  
17:30 - 18:00  
Speaker: Alessandro DiRocco (New York, United States)

**Paraneoplastic Autoimmune Movement Disorders**  
18:00 - 18:30  
Speaker: Thien T. Lim (George Town, Malaysia)

**Non-paraneoplastic Autoimmune Movement Disorders**  
18:30 - 19:00  
Speaker: Joseph Jankovic (Houston, United States)
OP-6, Oral Poster Presentation - Session VI Parkinsonian Syndromes / Behavior and Cognition

Chair: Yih-Ru Wu (Taoyuan, Taiwan)
Chair: Tiago Mestre (Ottawa, Canada)

Cognitive impairment in Parkinson’s disease: Correlation with Apolipoprotein E genetic polymorphism and plasma a-synuclein
Speaker: Nor Aslina Samat (Cheras, Malaysia)

LRRK2 GTPase domain variants in Dementia
Speaker: Xiao Jin Zhang (Singapore, Singapore)

Clinical and cardiac autonomic profile of Parkinsonian and cerebellar phenotypes of probable multiple system atrophy
Speaker: Malligurki Raghurama Rukmani (Bangalore, India)

Novel POLG mutation in a patient with early-onset parkinsonism, progressive external ophthalmoplegia and optic atrophy
Speaker: Lin Ma (Beijing, China)

Impulse control disorder frequency in different parkinsonism syndromes
Speaker: Muhittin Akbostanci (Ankara, Turkey)

Color vision impairment in Dementia with Lewy Bodies and prodromal Lewy bodies, a simple distinguishing feature from Alzheimer’s Dementia and prodromal Alzheimer’s disease
Speaker: Babak Tousi (Cleveland, United States)

Impact of frontal lobe function and behavioral changes on quality of life in patients with multiple system atrophy
Speaker: Lingyu Zhang (Chengdu, China)

Analysis of GWAS-linked variants in multiple system atrophy
Speaker: Xiaojing Gu (Chengdu, China)

Association analysis of SNP rs11868035 in SREBF1 with Parkinson’s disease, amyotrophic lateral sclerosis and multiple system atrophy in Chinese population
Speaker: Xiaoqin Yuan (Chengdu, China)

Diagnostic markers in the pathogenesis of parkinsonism syndrome development in chronic brain ischemia
Speaker: Khakim Khajibakiev (Tashkent, Uzbekistan)

Autonomic function tests in Parkinson’s disease and Multiple System Atrophy
Speaker: Trang Vo Nguyen Ngoc (Ho Chi Minh, Viet Nam)

Comparison of gait parameters between drug-naive patients with multiple system atrophy with predominant Parkinsonism and Parkinson’s disease
Speaker: Boo Suk Na (Seoul, Korea, Republic of)

Interrelationships between survival, sex and blood pressure in patients with multiple system atrophy
Speaker: Chava Peretz (Tel Aviv, Israel)

CSF biological markers of neurodegeneration in patients with Lewy Body Disease (LBD) and Progressive Supranuclear Palsy (PSP)
Speaker: Monika Frolova (Olomouc, Czech Republic)
G6, Genetics in Parkinson Disease and Movement Disorders

Learning Objectives
- To outline the genes associated with Parkinson and related diseases
- To describe the relationship between genotype and phenotype in parkinsonism
- To describe mitochondrial genetics in Parkinson disease and other movement disorders

Chair: Zbigniew Wszolek (Jacksonville, FL, United States)

08:30 - 09:00  Genetics of Parkinson Disease and Parkinson Disease-Like Genotypes
Speaker: Vincenzo Bonifati (Rotterdam, Netherlands)

09:00 - 09:30  Genetics of Parkinson Disease and Parkinson Disease-Like Phenotypes
Speaker: Robin Wu (Taipei, Taiwan)

09:30 - 10:00  Mitochondrial Genetics in Parkinson Disease and Other Movement Disorders
Speaker: Sheng-Di Chen (Shanghai, China)

G10, Other Hyperkinetic Disorders

Learning Objectives
- To summarize clinical aspects and treatment of myoclonus
- To summarize clinical aspects and treatment of chorea and tics
- To summarize clinical aspects and treatment of cerebellar syndromes

Chair: William Ondo (Houston, United States)

08:30 - 09:00  Myoclonus
Speaker: Jose Martin Rabey (Tel Aviv, Israel)

09:00 - 09:30  Chorea and Tics
Speaker: Karen Frei (Loma Linda, CA, United States)

09:30 - 10:00  Cerebellar Syndromes
Speaker: Shinsuke Fujioka (Fukuoka, Japan)

F7, Pathology of Parkinsonism and Related Disorders

Learning Objectives
- To describe alpha synuclein pathology in parkinsonism
- To explain the role of autophagy and the ubiquitin proteasome system in cells and their potential contribution to parkinsonian pathology
- To understand inflammation and other immune mechanisms in parkinsonian pathology

Chair: Peter Riederer (Wuerzburg, Germany)

08:30 - 09:00  Unfolding the Mystery of Alpha Synuclein
Speaker: Dennis Dickson (Jacksonville, FL, United States)
Breaking Down Autophagy and UPS  
Speaker: Young Jun Oh (Seoul, Korea, Republic of)  
09:00 - 09:30

Immune and Inflammatory Mechanisms in Parkinsonism  
Speaker: Ryuji Kaji (Tokushima, Japan)  
09:30 - 10:00

**E3, Challenging Hyperkinetic Movement Disorders: Spotlight on Ataxia, Chorea and Myoclonus**

**Learning Objectives**
- To recognize the signs of ataxia
- To distinguish choreas associated with different disorders
- To recognize and treat myoclonus

Chair: Jawad Bajwa (Riyadh, Saudi Arabia)

*Simplifying the Complicated World of Ataxia*  
Speaker: Achal Srivastava (New Delhi, India)  
08:30 - 09:00

*The Colorful Spectrum of Chorea: From Garden Variety to Rare Disorders*  
Speaker: Jan Roth (Praha, Czech Republic)  
09:00 - 09:30

*Understanding Myoclonus: Presentation, Work Up and Treatment*  
Speaker: Mark Hallett (Bethesda, MD, United States)  
09:30 - 10:00

**Timeline Parallel Session**

**F10, When It's Not Just Parkinson Disease: Associated Comorbidities and Other Movement Disorders**

**Learning Objectives**
- To describe the signs and management of sleep disorders and restless leg syndrome in Parkinson disease
- To explain the overlapping characteristics of essential tremor and Parkinson disease
- To understand the major comorbidities in Parkinson disease

Chair: Ivan Bodis-Wollner (Brooklyn, NY, United States)

*Sleep Disorders and Restless Legs Syndrome in Parkinson Disease*  
Speaker: Christian Baumann (Zurich, Switzerland)  
08:30 - 09:00

*The Overlap Between Essential Tremor and Parkinson Disease*  
Speaker: Alfonso Fasano (Toronto, Canada)  
09:00 - 09:30

*Comorbidities in Parkinson Disease*  
Speaker: Caroline Tanner (San Francisco, CA, United States)  
09:30 - 10:00

**Oral Poster Session**

**OP-7, Oral Poster Presentation - Session VII Hyperkinetic Movement Disorders**

Chair: Dirk Dressler (Hannover, Germany)
Chair: Paola Sandroni (New York, United States)
A clinical cross-sectional study of Huntington’s Disease patients from China  
Speaker: Wanglin Liu (Chengdu, China)

Shaky and unsteady: Dynamic posturography in essential tremor  
Speaker: Shweta Prasad (Bangalore, India)

Ocular motor disorders among X-linked Dystonia Parkinsonism (XDP) patients  
Speaker: Mabel Macas (Manila, Philippines)

Cervical dystonia: clinical features of 50 cases in Vietnam  
Speaker: Tai Tran (Ho Chi Minh, Viet Nam)

Evaluation of the relationship between cigarette smoking with risk of essential tremor in Singapore population  
Speaker: Fiona Setiawan (Singapore, Singapore)

Differential gene expression analysis reveals pathway based functional association of dysregulated genes in Friedreich’s ataxia  
Speaker: Himanshu Narayan Singh (Delhi, India)

Efficacy and safety of Valbenazine (NBI-98854) in subjects with tardive dyskinesia: Results of a long-term study (KINECT 3 extension)  
Speaker: Scott Siegert (San Diego, United States)

Stop signal reaction time in Cervical Dystonia and Parkinson’s patients  
Speaker: Akash Roy (Kolkata, India)

Writer’s Cramp: Brainstem connection revisited  
Speaker: Supriyo Choudhury (Kolkata, India)

Tremor in spinocerebellar ataxia type12 (SCA-12) mimics essential tremor (ET)  
Speaker: Manpreet Kaur Narang (New Delhi, India)

Volumetric magnetic resonance imaging differences in essential tremor compared to Parkinson’s disease  
Speaker: Giulia Franco (Nashville, United States)

Neuromodulation of NBIA-related dystonia  
Speaker: Tomasz Kmiec (Warszawa, Poland)

Preliminary evidence of functional compensation in premanifest Huntington’s disease using a novel visuospatial working memory task  
Speaker: Maria Soloveva (Melbourne, Australia)

Differences in botulinum toxin treated and non-treated cervical dystonia patients in somatosensory task-related functional imaging response  
Speaker: Martin Nevrly (Olomouc, Czech Republic)

Plenary Session  
10:30 - 11:45

I1, Movement Disorder Developments 2016-2017: Best articles published in Parkinsonism and Related Disorders

Chair: Vincenzo Bonifati (Rotterdam, Netherlands)  
Chair: Ronald Pfeiffer (Portland, OR, United States)  
Chair: Zbigniew Wszolek (Jacksonville, FL, United States)

Status of PRD  
10:30 - 11:00
Speaker: Ronald Pfeiffer (Portland, OR, United States)  
Speaker: Zbigniew Wszolek (Jacksonville, FL, United States)

Best Articles Published in Parkinsonism and Related Disorders  
11:00 - 11:45
Speaker: Eng-King Tan (Singapore, Singapore)  
Speaker: Andreas Puschmann (Lund, Sweden)
Melvin Yahr Awards

Chair: Daniel Truong (Fountain Valley, CA, United States)
Chair: Alessandro DiRocco (New York, United States)

Longitudinal effects of cognitive rehabilitation in Parkinson’s disease: a cognitive, clinical and neuroimaging study 11:45 - 11:55
Speaker: María Díez-Cirarda (Bilbao, Spain)

Volumetric magnetic resonance imaging differences in essential tremor compared to Parkinson’s disease 11:55 - 12:05
Speaker: Giulia Franco (Nashville, United States)

MicroRNA-4639 is a regulator of DJ-1 expression and a potential diagnostic marker for early Parkinson’s disease 12:05 - 12:15
Speaker: Yimeng Chen (Shanghai, China)